Skip to search formSkip to main contentSkip to account menu

MenACWY-CRM vaccine

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Meningococcal vaccine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Safety of a quadrivalent meningococcal conjugate vaccine in healthy subjects aged 9 months to 55 years in Vietnam
Meningococcal disease is a major global health concern due to its severe and sudden clinical manifestations, devastating long… 
Review
2017
Review
2017
Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine.
2016
2016
Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
2014
2014
1080Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination
Review
2013
Review
2013
Use of MenACWY-CRM in adolescents in the United States.
2012
2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
2010
2010
Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined…
ABSTRACT This study evaluated the safety, tolerability, and immunogenicity of an investigational quadrivalent meningococcal… 
2010
2010
omparison of the safety and immunogenicity of an investigational and a licensed uadrivalent meningococcal conjugate vaccine in children 2 – 10 years of age
Background: Routine administration of quadrivalent meningococcal conjugate vaccine to adolescents and certain high risk groups is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)